Introduction. Alzheimer’s disease (AD) is the commonest cause of dementia; its aetiology is unknown and there is nonspecific treatment to detain the course of the disease. The interferons (IFN) are proteins which have antiviral, antiproliferative and immunomodulating effects, and in the central nervous system these effects are mediated through the opiate receptors and the dopaminergic system. There is evidence that AD may be related to certain prion diseases and certain viruses, and that the IFN system has become deteriorated in this condition. Objective. We present a review of patients with AD treated with alpha interferon. Development. The first known case in the literature was that of a 69 year old man with definite AD (NINCDSADRDA) who was given alpha leucocytic IFN intrathecally and who initially was suspected of having CreutzfeldtJakob disease; after his treatment with IFNa, his neurological signs were observed to have stabilized. Subsequently, the results of a controlled, randomized, clinical trial were analyzed for 16 patients with probable EA (NINCDSADRDA) treated with recombinant IFNa2b intramuscularly, in whom no changes in clinical and neurophysiological assessment were observed after a year of treatment. However, there was a significant improvement in one of the variables used to measure quality of life, together with a certain reduction in mortality in the patients treated with IFNa. Conclusion. These results should be investigated in future studies in the light of current findings concerning the fact that, in the neurophysiological changes in AD, the proinflammatory cytokines, of which some of their numerous actions are blocked by IFNa, may produce a deleterious effect on the course of AD.
KeywordsAlzheimer’s diseaseClinical trialInterferonsInterferonaRecombinant interferona2bCategoriesDemenciaNeurodegeneraciónNeuropsiquiatríaPatología vascular
FULL TEXT(solo disponible en lengua castellana / Only available in Spanish)
Si ya es un usuario registrado en Neurologia, introduzca sus datos de inicio de sesión.
Rellene los campos para registrarse en Neurologia.com y acceder a todos nuestros artículos de forma gratuita
¿Olvidó su contraseña? Introduzca su correo electrónico y le haremos llegar una nueva
¡CONVIÉRTASE EN USUARIO PREMIUM DE NEUROLOGIA.COM!
Al hacerse premium, está apoyándonos para que Revista de Neurología
siga siendo uno de los referentes de habla hispana en la difusión del
conocimiento en neurociencias. ¡Gratuita tanto para autores como para
todos los usuarios de la web!
Además, por convertirte en usuario premium, recibirá las siguientes ventajas:
Plaza asegurada en todos nuestros Másteres (www.ineurocampus.com)
Descuento del 5% en los cursos de “Actualización en Neurología”, la FMC que estará disponible próximamente en la web.
Descarga gratuita en formato PDF dos de las obras con más éxito publicadas por Viguera Editores:
Oromotors Disorders in childhood (M. Roig-Quilis; L. Pennington)
Manual de Neuropsicología 2ª ed. (J. Tirapu-Ustárroz; M. Ríos-Lago; F. Maestú)
El precio para hacerse Premium durante el periodo de un año es de 5€, que podrá pagar a continuación a través de una pasarela de pago seguro con tarjeta de crédito, transferencia bancaria o PayPal:
OPEN ACCESS
